Get the Stockscreener App
3.29
0.00%
0.00
After Hours:
3.34
0.05
+1.52%
Tenaya Therapeutics Inc stock is traded at $3.29, with a volume of 8.63M.
It is up +0.00% in the last 24 hours and up +72.25% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
See More
Previous Close:
$3.29
Open:
$3.58
24h Volume:
8.63M
Relative Volume:
3.61
Market Cap:
$243.17M
Revenue:
-
Net Income/Loss:
$-117.23M
P/E Ratio:
-1.4753
EPS:
-2.23
Net Cash Flow:
$-95.25M
1W Performance:
+48.20%
1M Performance:
+72.25%
6M Performance:
-27.53%
1Y Performance:
+73.16%
1-Day Range:
$2.95
$3.70
1-Week Range:
$2.08
$3.70
52-Week Range:
$1.61
$7.01
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
3.29 | 243.17M | 0 | -117.23M | -95.25M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Around the Helix: Cell and Gene Therapy Company Updates – November 27, 2024 - CGTLive™
First Patient Dosed in RIDGE-1 Trial for Tenaya’s ARV Cardiomyopathy Gene Therapy TN-401 - CGTLive™
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase - GlobeNewswire
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy - Yahoo Canada Finance
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $14.75 Average Target Price from Brokerages - MarketBeat
Tenaya Therapeutics Reports Q3 2024 Progress and Financial Results - TipRanks
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Tenaya Therapeutics Issues Stock Options to New Employees at $1.97 Per Share | TNYA Stock News - StockTitan
Tenaya Therapeutics SVP sells $4,786 in stock By Investing.com - Investing.com UK
Tenaya Therapeutics SVP sells $4,786 in stock - Investing.com
RA Capital Management's Strategic Acquisition in Tenaya Therapeu - GuruFocus.com
Leerink Partnrs Issues Optimistic Estimate for TNYA Earnings - MarketBeat
Research Analysts Offer Predictions for TNYA FY2024 Earnings - MarketBeat
William Blair Brokers Increase Earnings Estimates for TNYA - MarketBeat
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) large institutional owners must be happy as stock continues to impress, up 42% over the past week - Simply Wall St
Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $18.00 at Chardan Capital - MarketBeat
Latham Group, Inc. to Participate in the Baird 2024 Global Industrial Conference - The Manila Times
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
abrdn plc Invests $1.06 Million in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - MarketBeat
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Piper Sandler raises confidence in Tenaya Therapeutics stock ahead of December data, reiterates Overweight rating - Investing.com Australia
Tenaya shares retain stock target, buy rating on safety milestone - Investing.com
Tenaya shares hold buy rating, positive outlook on trial progress - Investing.com
Tenaya Therapeutics' (TNYA) "Buy" Rating Reiterated at Canaccord Genuity Group - MarketBeat
Leerink sees Tenaya's trial update as positive, maintains price target By Investing.com - Investing.com UK
Tenaya stock undervalued despite strong Ph1 safety update, says Canaccord - Investing.com
Tenaya (TNYA) Experiences Notable Stock Increase Following Key Update - Stocks Telegraph
Tenaya advances gene therapy trial for heart condition - Investing.com
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM - GlobeNewswire
SVP, Accounting and Fin. Ops. Saito Chihiro sold 2,363 shares of Tenaya Therapeutics Inc [TNYA] - Knox Daily
Tenaya Therapeutics stock hits 52-week low at $1.63 By Investing.com - Investing.com Canada
Technical analysis of Tenaya Therapeutics Inc (TNYA) stock chart patterns - US Post News
A Closer Look at Tenaya Therapeutics Inc (TNYA) Stock Gains - The InvestChronicle
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of “Buy” by Brokerages - Defense World
Hypertrophic Cardiomyopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing - Barchart
Charting the Course: Tenaya Therapeutics Inc’s TNYA Stock Prospects - The InvestChronicle
Tenaya Therapeutics Inc (TNYA) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Daily Progress: Tenaya Therapeutics Inc (TNYA) Drop -3.11, Closing at 1.87 - The Dwinnex
Tenaya Therapeutics Inc [TNYA] Insider Activity: An Update for Investors - Knox Daily
Canaccord keeps buy rating, price target on Tenaya shares - Investing.com
Tenaya Therapeutics' SWOT analysis: gene therapy stock poised for pivotal catalysts By Investing.com - Investing.com South Africa
Tenaya Therapeutics' SWOT analysis: gene therapy stock poised for pivotal catalysts - Investing.com India
Myocardial Infarction Global Market Report 2024 Size and Forecast - WhaTech
Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles - Business Wire
A closer look at Tenaya Therapeutics Inc (TNYA)’s stock price trends - US Post News
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):